Vericel (VCEL) Goodwill & Intangibles (2014 - 2026)
Vericel (VCEL) posted Goodwill & Intangibles of $5.3 million for Q2 2026, down 2.85% sequentially from $5.5 million in Q1 2026, and down 10.53% YoY from $5.9 million in Q2 2025.
Analysis
Vericel (VCEL) Goodwill & Intangibles (2014 - 2026) Analysis & Trends
Vericel has reported Goodwill & Intangibles for 8 years, with the latest figure at $5.3 million in Q2 2026.
- Quarterly Goodwill & Intangibles fell 10.53% year-over-year to $5.3 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $5.3 million (down 10.53% YoY) and the FY2025 annual result came in at $5.6 million, down 10.0% from the prior year.
- Goodwill & Intangibles eased to $5.3 million in Q2 2026 per VCEL's latest filing, from $5.5 million in the prior quarter.
- Over five years, Goodwill & Intangibles peaked at $7.5 million in Q4 2022 and troughed at $5.3 million in Q2 2026.
- A 5-year average of $6.4 million and a median of $6.4 million in 2024 frame the typical range for Goodwill & Intangibles.
- The sharpest annual moves came in 2023 and 2026: Goodwill & Intangibles dropped 8.33% in 2023, then slipped 10.53% in 2026.
- Over 5 years, Goodwill & Intangibles stood at $7.5 million in 2022, then fell by 8.33% to $6.9 million in 2023, then dropped by 9.09% to $6.2 million in 2024, then declined by 10.0% to $5.6 million in 2025, then dropped by 5.55% to $5.3 million in 2026.
- According to Business Quant data, Goodwill & Intangibles over the past three periods registered $5.3 million, $5.5 million, and $5.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Vericel | 2.05 Bn | 1.89 Bn | 56.40 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 5.31 Mn |
| Mar 31, 2026 | 5.47 Mn |
| Dec 31, 2025 | 5.63 Mn |
| Sep 30, 2025 | 5.78 Mn |
| Jun 30, 2025 | 5.94 Mn |
| Mar 31, 2025 | 6.09 Mn |
| Dec 31, 2024 | 6.25 Mn |
| Sep 30, 2024 | 6.41 Mn |
| Jun 30, 2024 | 6.56 Mn |
| Mar 31, 2024 | 6.72 Mn |
| Dec 31, 2023 | 6.88 Mn |
| Sep 30, 2023 | 7.03 Mn |
| Jun 30, 2023 | 7.19 Mn |
| Mar 31, 2023 | 7.34 Mn |
| Dec 31, 2022 | 7.50 Mn |
| Sep 30, 2016 | 2.71 Mn |
| Jun 30, 2016 | 2.78 Mn |
| Mar 31, 2016 | 2.85 Mn |
| Dec 31, 2015 | 2.92 Mn |
| Sep 30, 2015 | 2.99 Mn |